Compare Oracle Corporation (ORCL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Oracle Corporation trades at $162.75 (market cap $468.13B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Oracle Corporation is far larger — about 251.7× Recursion Pharmaceuticals Inc's market cap, and Oracle Corporation pays a 1.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ORCL | RXRX | |
|---|---|---|
Market Cap | $468.13B | $1.86B |
Sector | Technology | Health |
52-Week High | $328.33 | $6.79 |
52-Week Low | $114.99 | $2.84 |
Enterprise Value | $597.38B | $1.38B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $161.70, up 1.81% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $57.40B in 2025, with net income margin expanding to 25.37%. The stock is supported by positive AI infrastructure developments and a consensus analyst price target of $243.38, indicating significant upside potential from current levels.
The outlook remains positive driven by AI partnerships and cloud growth, but risks include high valuation multiples and rising capital expenditures. Institutional sentiment is bullish with 65% buy ratings, though legal scrutiny and competitive pressures warrant monitoring for sustained momentum.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
